# Enzymatica > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/enzymatica). ## Overview Enzymatica is a Swedish life science company that develops and sells medical products for infection-related conditions based on its Penzyme barrier technology. Its core product is ColdZyme, a mouth spray for colds and cold-like symptoms, and the business is organized around in-house enzyme production, regulatory know-how, and partner-led commercialization in selected markets. ## Products & services • ColdZyme mouth spray for colds • Penzyme-based barrier technology • In-house enzyme production • Regulatory and clinical documentation • Partner-led marketing and distribution • Contract filling and packaging - **ColdZyme consumer health products** (85%) — Mouth spray products based on barrier technology for colds and cold-like symptoms. - **Enzyme production and technology platform** (10%) — Internal production of marine enzymes and related know-how that support the product platform. - **Regulatory and clinical support** (5%) — Documentation, approvals, and scientific support used to maintain market access and partnerships. - ColdZyme mouth spray for colds - Penzyme-based barrier technology - In-house enzyme production - Regulatory and clinical documentation - Partner-led marketing and distribution - Contract filling and packaging ## Customers Enzymatica sells primarily into consumer health channels, where end users buy ColdZyme for relief from colds and upper respiratory symptoms. Commercial partners, distributors, and local market operators are also key customers because they handle marketing, sales, and distribution in many countries. In Sweden, the UK, and Iceland, the company also manages sales and marketing directly, giving it direct access to consumers and market feedback. - **Consumers with cold and cold-like symptoms** (primary) — Buy ColdZyme for symptom relief and convenience in self-care settings - **Consumer health partners and distributors** (primary) — Buy rights, supply, and support to market and distribute ColdZyme locally - **Pharmacy and retail channels** (secondary) — Stock the product for over-the-counter consumer purchase and repeat use - **Direct-market consumers in owned markets** (secondary) — Purchase through markets where Enzymatica manages sales and marketing directly - Consumers seeking relief from colds and cold-like symptoms - Consumer health distributors and local market partners - Retail and pharmacy channels in priority markets - Direct sales and marketing markets: Sweden, UK, Iceland - Partners that need regulatory and brand support ## Geography Enzymatica is headquartered in Lund, Sweden, with key operational functions also in Reykjavik, Iceland. The company commercializes through partners across international markets, with direct sales and marketing in Sweden, the United Kingdom, and Iceland, and it is focused on relaunching and expanding in selected EEA and other priority cold-remedy markets. - **Sweden** — Direct sales and marketing market - **United Kingdom** — Direct sales and marketing market - **Iceland** — Production and direct market presence - **Europe** — Selected EEA and European partner markets - Headquartered in Lund, Sweden - Enzyme production facility in Reykjavik, Iceland - Direct sales and marketing in Sweden, the UK, and Iceland - Partner-led expansion in selected EEA markets - International launches depend on local regulation and approvals ## Strategy Enzymatica’s strategy is built around expanding through local partners, relaunching ColdZyme in markets where it already has MDR approval, and broadening the product portfolio around its barrier technology. Scientific evidence, regulatory documentation, and partner selection are central to the model because they support market access and brand credibility in regulated consumer health markets. - **Partner-led international expansion** (medium-term) — Local partners provide market access, sales capability, and regulatory familiarity without requiring a large local footprint - **Relaunch in selected EEA markets** (short-term) — Existing MDR approvals can shorten time to market and improve the economics of re-entry - **Product portfolio development** (medium-term) — A broader portfolio can reduce dependence on a single product and extend the barrier-technology platform - **Scientific and regulatory validation** (short-term) — Clinical evidence and documentation support approvals, partner discussions, and consumer trust - Expand through local commercial partners - Relaunch ColdZyme in MDR-approved EEA markets - Develop new products from the barrier technology platform - Strengthen scientific evidence and regulatory support - Focus on priority cold-remedy markets ## Risks Enzymatica depends on external financing, partner execution, and continued regulatory acceptance in markets where medical-device rules can change. The business also faces competition from larger consumer-health companies, IT and cybersecurity exposure, and production/supply-chain risks because manufacturing is split between in-house enzyme production and external contract manufacturing. - **Funding and capital access** [high] — The company needs external financing to fund research, regulatory work, and market expansion - **Partner distribution dependence** [high] — Sales in many markets rely on third-party partners, so weak partner execution directly limits revenue - **Regulatory and classification risk** [high] — Medical-device rules, approvals, and product classification can change market access and documentation needs - **Competition** [medium] — Larger rivals may offer stronger brands, lower prices, or more effective products - **Cybersecurity and IT disruption** [medium] — Production, quality, and communication depend on functioning systems and data protection - **Production and supply-chain dependence** [medium] — The model combines in-house enzyme production with external filling and packaging partners - Funding needs may limit execution if capital access weakens - Partner-led sales can be slow to rebuild in key markets - Regulatory changes could affect product classification or approvals - Competition from larger consumer-health players may pressure market share - IT, cybersecurity, and supply-chain failures could disrupt operations ## Accounting Enzymatica’s reporting is shaped by judgment around development-cost capitalization, goodwill impairment testing, and foreign-currency translation as the business expands internationally. Because the company uses a mix of in-house production and contract manufacturing, investors should also watch inventory, production cost allocation, and any timing effects from regulatory or market-launch milestones. - **Development cost capitalization** — Can materially affect operating profit and balance-sheet intangibles - **Goodwill impairment testing** — Impairment could reduce equity and earnings materially - **Foreign currency translation** — Can create volatility in reported results and equity reserves - **Contract manufacturing and inventory timing** — Can influence gross margin and inventory valuation - Development costs may be capitalized or expensed based on quarterly judgment - Goodwill is tested annually for impairment - Foreign-currency translation affects foreign subsidiaries and international transactions - Contract manufacturing can affect inventory and cost timing - IFRS 18 may change presentation but not underlying measurement --- *Last updated: 2026-08-11T04:04:52.027836+00:00*